Skip to content
← Full study record

NCT01212991 · MORE INFO

Limitations, agreements, and source contact

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer · Source last updated 2020-03-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than study data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any invention described.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov_Inquiries@pfizer.com
organization
Pfizer Inc.
phone
8007181021
title
Pfizer ClinicalTrials.gov Call Center
Complete source fields
certain Agreement
other Details
PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than study data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any invention described.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov_Inquiries@pfizer.com
organization
Pfizer Inc.
phone
8007181021
title
Pfizer ClinicalTrials.gov Call Center

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice